0001193125-24-037078.txt : 20240215 0001193125-24-037078.hdr.sgml : 20240215 20240215080603 ACCESSION NUMBER: 0001193125-24-037078 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20240214 ITEM INFORMATION: Material Modifications to Rights of Security Holders ITEM INFORMATION: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240215 DATE AS OF CHANGE: 20240215 FILER: COMPANY DATA: COMPANY CONFORMED NAME: VACCINEX, INC. CENTRAL INDEX KEY: 0001205922 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 161603202 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38624 FILM NUMBER: 24642187 BUSINESS ADDRESS: STREET 1: 1895 MOUNT HOPE AVE CITY: ROCHESTER STATE: NY ZIP: 14620 BUSINESS PHONE: 585-271-2700 MAIL ADDRESS: STREET 1: 1895 MOUNT HOPE AVE CITY: ROCHESTER STATE: NY ZIP: 14620 FORMER COMPANY: FORMER CONFORMED NAME: VACCINEX INC DATE OF NAME CHANGE: 20021114 8-K 1 d754295d8k.htm 8-K 8-K
NASDAQ false 0001205922 --12-31 0001205922 2024-02-14 2024-02-14

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 14, 2024

 

 

Vaccinex, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-38624   16-1603202

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

1895 Mount Hope Avenue, Rochester, New York   14620
(Address of principal executive offices)   (Zip Code)

(585) 271-2700

(Registrant’s telephone number, including area code)

 

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
Symbol(s)

  

Name of each exchange

on which registered

Common Stock, par value $0.0001 per share   VCNX   Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 3.03

Material Modification to Rights of Security Holders.

To the extent required by Item 3.03 of Form 8-K, the information contained in Item 5.03 of this Current Report on Form 8-K is incorporated herein by reference.

 

Item 5.03

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

On February 14, 2024, Vaccinex, Inc. (the “Company”) filed a Certificate of Amendment (the “Amendment”) to the Company’s Amended and Restated Certificate of Incorporation, as amended, with the Delaware Secretary of State to implement a reverse stock split of the Company’s issued shares of common stock at a ratio of 1-for-14, effective at 5:00 p.m. Eastern Time on Monday February 19, 2024 (the “Reverse Stock Split”), previously approved by the Company’s Board of Directors. As a result of the Reverse Stock Split, every fourteen shares of the Company’s issued common stock will automatically be combined into one share of common stock. The Reverse Stock Split will affect all stockholders uniformly and will not alter any stockholders’ percentage interest in the Company’s common stock, except to the extent that the Reverse Stock Split results in any of our stockholders receiving whole shares in lieu of fractional shares as further described below. Any fractional shares resulting from the Reverse Stock Split will be rounded up to the nearest whole share. Proportionate adjustments for the Reverse Stock Split will be made to the exercise prices and number of shares issuable under the Company’s equity incentive plans, and the number of shares underlying outstanding equity awards, as applicable. The Reverse Stock Split will not change the par value of the common stock, modify any voting rights or other terms of the common stock, or change the number of authorized shares of the Company.

The Company expects that its common stock will begin trading on the Nasdaq Stock Market on a post-Reverse Stock Split basis under the Company’s existing trading symbol “VCNX” when the market opens on Tuesday February 20, 2024. The new CUSIP number for the Company’s common stock post-Reverse Stock Split is 918640301.

The foregoing summary of the Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Amendment, a copy of which is attached hereto as Exhibit 3.1 and is incorporated herein by reference.

 

Item 8.01

Other Events.

On February 15, 2024, the Company issued a press release announcing the Reverse Stock Split. A copy of the press release is attached as Exhibit 99.1 to this report.

Forward Looking Statements

Except for the factual statements made herein, information contained in this report consists of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that are difficult to predict. Words such as “will,” “may,” “intends,” “plans,” and similar expressions, or the use of future tense, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. Such forward-looking statements are not guarantees of performance and actual actions or events could differ materially from those contained in such statements. For example, there can be no assurance that the Company will be able to regain compliance with the Nasdaq Listing standards. The risks included are not exhaustive; for a more detailed description of these uncertainties and other factors, see the other risk factors set forth from time to time in the Company’s filings with the Securities and Exchange Commission, copies of which are available for free at www.sec.gov or upon request from the Company’s Investor Relations Department. All information provided in this Form 8-K is as of the date hereof and the Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law.

 

Item 9.01

Financial Statements and Exhibits.

 

Exhibit
No.

   

Description

 3.1    Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Vaccinex, Inc., effective as of February 19, 2024
99.1    Press Release, dated February 15, 2024
104    Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

      VACCINEX, INC.
Date: February 15, 2024    
    By:  

/s/ Scott E. Royer

      Scott E. Royer
      Chief Financial Officer
 EX-3.1 2 d754295dex31.htm EX-3.1 EX-3.1

Exhibit 3.1

CERTIFICATE OF AMENDMENT

OF THE

AMENDED AND RESTATED CERTIFICATE OF INCORPORATION

OF

VACCINEX, INC.

VACCINEX, INC., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “General Corporation Law”), hereby certifies as follows:

FIRST: The name of the corporation is Vaccinex, Inc. (the “Corporation”).

SECOND: The Amended and Restated Certificate of Incorporation of the Corporation was filed with the Secretary of State of the State of Delaware on August 13, 2018 and was amended by that Certificate of Amendment filed with the Secretary of State of the State of Delaware on September 22, 2023 (the “Certificate of Incorporation”).

THIRD: The Certificate of Incorporation is hereby amended as follows:

Paragraph 1 of Article IV of the Certificate of Incorporation is hereby amended in its entirety to provide as follows:

“The total number of shares of all classes of stock that the Corporation has authority to issue is 110,000,000 shares, consisting of two classes: 100,000,000 shares of common stock, $0.0001 par value per share (the “Common Stock”), and 10,000,000 shares of preferred stock, $0.001 par value per share (the “Preferred Stock”).

Effective at 5:00 p.m., Eastern time, on February 19, 2024 (the “Effective Time”), a one-for-fourteen reverse stock split of the Corporation’s Common Stock shall become effective, pursuant to which each fourteen shares of Common Stock issued and held of record by each stockholder of the Corporation, or held by the Corporation in treasury stock, immediately prior to the Effective Time shall be reclassified and combined into one validly issued, fully-paid and nonassessable share of Common Stock automatically and without any action by the holder thereof upon the Effective Time and shall represent one share of Common Stock from and after the Effective Time (such reclassification and combination of shares, the “Reverse Stock Split”). The par value of the Common Stock following the Reverse Stock Split shall remain at $0.0001 per share.

No fractional shares of Common Stock shall be issued as a result of the Reverse Stock Split. In lieu thereof, any holder who would otherwise be entitled to a fractional share of Common Stock as a result of the Reverse Stock Split, following the Effective Time, shall be entitled to receive one (1) additional whole share of Common Stock; provided that, whether or not fractional shares would be issuable as a result of the Reverse Stock Split shall be determined on the basis of (a) the total number of shares of Common Stock that were issued and outstanding immediately prior to the Effective Time and

(b) the aggregate number of shares of Common Stock after the Effective Time into which the shares of Common Stock have been reclassified; and with respect to holders of shares of Common Stock in book-entry form in the records of the Corporation’s transfer agent that were issued and outstanding immediately prior to the Effective Time, any holder who would otherwise be entitled to a fractional share of Common Stock as a result of the Reverse Stock Split, following the Effective Time, shall be entitled to receive one (1) additional share of Common Stock automatically and without any action by the holder.

Beginning at the Effective Time, each certificate representing pre-Reverse Stock Split shares of Common Stock will be deemed for all corporate purposes to evidence ownership of post-Reverse Stock Split shares.”

FOURTH: This Certificate of Amendment shall become effective on February 19, 2024 at 5:00 p.m. Eastern Time.

FIFTH: This amendment has been duly adopted by the Board of Directors of the Corporation and approved by the Corporation’s stockholders in accordance with Section 242 of the General Corporation Law.

[Signature page follows.]

 

 

2

IN WITNESS WHEREOF, the Company has caused this Certificate of Amendment to be signed by its duly authorized officer on this 14th day of February 2024.

 

By:  

/s/ Maurice Zauderer

  Maurice Zauderer
  President and Chief Executive Officer
 EX-99.1 3 d754295dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

Vaccinex, Inc. Announces Reverse Stock Split

ROCHESTER, N.Y., February 15, 2024 (GLOBE NEWSWIRE) – Vaccinex, Inc., (NASDAQ: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of SEMA4D, today announced that it will effect a 1-for-14 reverse stock split of its issued common stock, effective at 5:00 p.m. Eastern Time on Monday, February 19, 2024. Beginning Tuesday, February 20, 2024, the Company’s common stock will trade on a split-adjusted basis.

At the Company’s Special Meeting of Stockholders held on February 8, 2024, the Company’s stockholders approved a proposal to authorize a reverse stock split of the Company’s common stock, at a ratio of 1-for-4, 1-for-6, 1-for-8, 1-for-10, 1-for-12, and 1-for-14, as to be determined by the Company’s Board of Directors. The Board of Directors approved a 1-for-14 reverse split ratio, and on Wednesday, February 14, 2024, the Company filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation to effect the reverse stock split effective as of 5:00 p.m. Eastern Time on Monday, February 19, 2024 (the “Effective Time”).

The Company’s Board of Directors implemented the reverse stock split with the objective of regaining compliance with the $1.00 minimum bid price requirement of The Nasdaq Capital Market. The Company has until March 4, 2024 to comply with this requirement. To evidence compliance with this requirement, the closing bid price of the Company’s common stock must be at least $1.00 per share for a minimum of 10 consecutive business days by March 4, 2024.

The Company’s shares of common stock will continue to trade on The Nasdaq Capital Market under the symbol “VCNX.” The new CUSIP number for the Company’s common stock post-reverse stock split is 918640301.

As a result of the reverse stock split, every fourteen shares of the Company’s common stock will automatically be combined into one share of common stock. The reverse stock split will affect all stockholders uniformly and will not alter any stockholder’s percentage ownership interest in the Company’s equity, except to the extent that the reverse stock split results in any of our stockholders receiving whole shares in lieu of fractional shares, as discussed below. Any fraction of a share of common stock that would be created as a result of the reverse stock split will be rounded up to the next whole share. There will not be a reduction in the total number of authorized shares of common stock.

As of the Effective Time, the number of shares of common stock available for issuance under the Company’s equity incentive plans and issuable pursuant to equity awards immediately prior to the reverse stock split will be proportionately adjusted by the reverse stock split. The exercise prices of the Company’s outstanding options will be adjusted in accordance with their respective terms.

LOGO

The combination of, and reduction in, the number of issued shares of common stock as a result of the reverse stock split will occur automatically at the Effective Time without any additional action on the part of our stockholders. The Company’s transfer agent, Computershare, Inc., is acting as the exchange agent for the reverse stock split and will send stockholders a transaction statement indicating the number of shares of common stock stockholders hold after the reverse stock split. Stockholders owning shares via a broker, bank, trust or other nominee will have their positions automatically adjusted to reflect the reverse stock split, subject to such broker’s particular processes, and will not be required to take any action in connection with the reverse stock split. Additional information regarding the reverse stock split is available on the Form 8-K filed today, as well as in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on January 8, 2024, a copy of which is available at www.sec.gov and on the Company’s website.

About Vaccinex Inc.

Vaccinex, Inc. is pioneering a differentiated approach to treating slowly progressive neurodegenerative diseases and cancer through the inhibition of semaphorin 4D (SEMA4D). The Company’s lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes triggers damaging inflammation in chronic diseases of the brain and prevents immune infiltration into tumors. In neurodegenerative diseases, pepinemab is being studied as a monotherapy in the Phase 1/2a SIGNAL-AD study in Alzheimer’s Disease, with ongoing exploration of potential Phase 3 development in Huntington’s disease. In oncology, pepinemab is being evaluated in combination with KEYTRUDA® in the Phase 1b/2 KEYNOTE-B84 study in recurrent or metastatic head and neck cancer (HNSCC) and in combination with BAVENCIO® in a Phase 1b/2 study, supported by funding from Gateway Discovery Foundation, in patients with metastatic pancreatic adenocarcinoma (PDAC). The oncology clinical program also includes several investigator-sponsored studies in solid tumors including breast cancer and melanoma.

 

LOGO

Forward-Looking Statements

To the extent that statements contained in this press release are not descriptions of historical facts regarding Vaccinex, Inc. (“Vaccinex,” “we,” “us,” or “our”), they are forward-looking statements reflecting management’s current beliefs and expectations. Such statements include, but are not limited to, statements about our plans, expectations and objectives with respect to the results and timing of the reverse stock split, the effect the reverse stock split will have on the Company’s ability to regain compliance with the Nasdaq Listing standards, and other statements identified by words such as “will,” “objective,” and similar expressions or their negatives (as well as other words and expressions referencing future events, conditions, or circumstances). Forward-looking statements involve substantial risks and uncertainties that could cause the outcome of our research and pre-clinical development programs, clinical development programs, future results, performance, or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, uncertainties inherent in the execution, cost and completion of preclinical studies and clinical trials, that interim and preliminary data may not be predictive of final results and does not ensure success in later clinical trials, uncertainties related to regulatory approval, risks related to our

dependence on our lead product candidate pepinemab, the impact of the COVID-19 pandemic, the possible delisting of our common stock from NASDAQ if we are unable to regain compliance with the NASDAQ listing standards, and other matters that could affect our development plans or the commercial potential of our product candidates. Except as required by law, we assume no obligation to update these forward-looking statements. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, see the section titled “Risk Factors” in our periodic reports filed with the Securities and Exchange Commission (“SEC”) and the other risks and uncertainties described in the Company’s annual year-end Form 10-K and subsequent filings with the SEC.

Investor Contact

Elizabeth Evans, PhD

Chief Operating Officer, Vaccinex, Inc.

(585) 766-2033

eevans@vaccinex.com

EX-101.SCH 4 vcnx-20240214.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 5 vcnx-20240214_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Security Exchange Name Security Exchange Name Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period EX-101.PRE 6 vcnx-20240214_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 g754295page8.jpg GRAPHIC begin 644 g754295page8.jpg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end XML 8 R1.htm IDEA: XBRL DOCUMENT v3.24.0.1
Document and Entity Information
Feb. 14, 2024
Cover [Abstract]  
Security Exchange Name NASDAQ
Amendment Flag false
Entity Central Index Key 0001205922
Current Fiscal Year End Date --12-31
Document Type 8-K
Document Period End Date Feb. 14, 2024
Entity Registrant Name Vaccinex, Inc.
Entity Incorporation State Country Code DE
Entity File Number 001-38624
Entity Tax Identification Number 16-1603202
Entity Address, Address Line One 1895 Mount Hope Avenue
Entity Address, City or Town Rochester
Entity Address, State or Province NY
Entity Address, Postal Zip Code 14620
City Area Code (585)
Local Phone Number 271-2700
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, par value $0.0001 per share
Trading Symbol VCNX
Entity Emerging Growth Company true
Entity Ex Transition Period false

EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 1 24 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://vaccinex.com//20240214/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d754295d8k.htm vcnx-20240214.xsd vcnx-20240214_lab.xml vcnx-20240214_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 17 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "d754295d8k.htm": { "nsprefix": "vcnx", "nsuri": "http://vaccinex.com/20240214", "dts": { "inline": { "local": [ "d754295d8k.htm" ] }, "schema": { "local": [ "vcnx-20240214.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd" ] }, "labelLink": { "local": [ "vcnx-20240214_lab.xml" ] }, "presentationLink": { "local": [ "vcnx-20240214_pre.xml" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 4, "http://xbrl.sec.gov/dei/2023": 4 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 25, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://vaccinex.com//20240214/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "duration_2024-02-14_to_2024-02-14", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d754295d8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "duration_2024-02-14_to_2024-02-14", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d754295d8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://vaccinex.com//20240214/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://vaccinex.com//20240214/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://vaccinex.com//20240214/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://vaccinex.com//20240214/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://vaccinex.com//20240214/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://vaccinex.com//20240214/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://vaccinex.com//20240214/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://vaccinex.com//20240214/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://vaccinex.com//20240214/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://vaccinex.com//20240214/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://vaccinex.com//20240214/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://vaccinex.com//20240214/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r7" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://vaccinex.com//20240214/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://vaccinex.com//20240214/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://vaccinex.com//20240214/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://vaccinex.com//20240214/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://vaccinex.com//20240214/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://vaccinex.com//20240214/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://vaccinex.com//20240214/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://vaccinex.com//20240214/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security 12b Title", "terseLabel": "Security 12b Title", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://vaccinex.com//20240214/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://vaccinex.com//20240214/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "terseLabel": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://vaccinex.com//20240214/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://vaccinex.com//20240214/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "terseLabel": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 18 0001193125-24-037078-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-24-037078-xbrl.zip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ǔ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end XML 19 d754295d8k_htm.xml IDEA: XBRL DOCUMENT 0001205922 2024-02-14 2024-02-14 NASDAQ false 0001205922 --12-31 8-K 2024-02-14 Vaccinex, Inc. DE 001-38624 16-1603202 1895 Mount Hope Avenue Rochester NY 14620 (585) 271-2700 false false false false Common Stock, par value $0.0001 per share VCNX true false